Research map: Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer

Back to the article

Papers in this map

  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types · Robert M. Samstein · 2019 · 4457 citations · Cited by this paper
  2. Perspectives on shared decision making related to medications from patients with multiple long-term conditions transitioning from hospital to home: a qualitative study · 2026 · Related
  3. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer · Patrick M. Forde · 2022 · 2741 citations · Cited by this paper
  4. Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections · 2026 · Related
  5. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer · Ramón Rami–Porta · 2024 · 372 citations · Cited by this paper
  6. Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation” · 2026 · Related
  7. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee · Lynette Marie Sholl · 2020 · 298 citations · Cited by this paper
  8. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System · 2026 · Related
  9. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma · Nan Zhang · 2024 · 97 citations · Cited by this paper
  10. Patient perspectives on atrial fibrillation management and pharmacist roles in outpatient clinics: a qualitative study · 2026 · Related
  11. Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC · Dongchen Sun · 2023 · 91 citations · Cited by this paper
  12. Active surveillance and risk prediction of piperacillin/tazobactam‑associated hypokalaemia: development and external validation of a clinical nomogram · 2026 · Related
  13. Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer · Ravi Rajaram · 2023 · 85 citations · Cited by this paper
  14. Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study · 2026 · Related
  15. IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity · Kelly Dare Moynihan · 2024 · 75 citations · Cited by this paper
  16. Grounding clinical supervision in advanced pharmacy practice: a new conceptual model · 2026 · Related
  17. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC · Yixin Zhou · 2024 · 64 citations · Cited by this paper
  18. A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England · 2026 · Related
  19. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases · Antero Salminen · 2024 · 58 citations · Cited by this paper
  20. A qualitative exploration of healthcare professionals’ perspectives on the role of pharmacists in screening older adults for depression during medication reviews · 2026 · Related
  21. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer · Zhen Han · 2024 · 57 citations · Cited by this paper
  22. Optimisation and evaluation of the random forest model in the efficacy prediction of chemoradiotherapy for advanced cervical cancer based on radiomics signature from high-resolution T2 weighted images · Defeng Liu · 2021 · 40 citations · Cited by this paper
  23. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies · Yizhou Zhang · 2024 · 17 citations · Cited by this paper
  24. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer · Jiehan Jiang · 2021 · 16 citations · Cited by this paper
  25. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma · Hongyan Xu · 2022 · 14 citations · Cited by this paper
  26. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer · Osama M. Mosalem · 2024 · 14 citations · Cited by this paper
  27. Tumor mutational burden and efficacy of chemotherapy in lung cancer · Juan Song · 2022 · 11 citations · Cited by this paper
  28. Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study · Zhanming Ma · 2025 · 10 citations · Cited by this paper
  29. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy · Jiajia Du · 2024 · 7 citations · Cited by this paper
  30. Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma · Yizhe Mao · 2026 · 6 citations · Cited by this paper
  31. Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials · Weiming Zhang · 2024 · 5 citations · Cited by this paper
  32. Nomogram for Predicting Efficacy and Prognosis After Chemotherapy for Advanced NSCLC · Jiaying Gao · 2024 · 3 citations · Cited by this paper
  33. Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer. · Y-M Zhang · 2024 · 3 citations · Cited by this paper
  34. Sleeve lobectomy versus lobectomy after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading the lobar bronchial orifice: a multicenter retrospective cohort study · Tianyue Ma · 2025 · 3 citations · Cited by this paper
  35. Regularity and correlation analysis of regional lymph node metastasis in nonoperative patients with non-small cell lung cancer based on positron emission tomography/computed tomography images · Feifan Sun · 2024 · 2 citations · Cited by this paper
  36. Prognostic significance of eighth edition TNM stage criteria in combined small-cell lung cancer · Ziran Zhao · 2023 · 1 citation · Cited by this paper
  37. Creating a Proxy for Baseline Eastern Cooperative Oncology Group Performance Status in Electronic Health Records for Comparative Effectiveness Research in Advanced Non–Small Cell Lung Cancer · Michael William Johnson · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)